Eli Lilly's profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...
Eli Lilly (LLY) stock rises as company posts Q4 2024 results, beating expectations with a twofold rise in revenue from weight ...
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.
Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of non-incretin products, which grew sales 20% in the fourth quarter, should “help ...
Hosted on MSN10h
Eli Lilly's Blockbuster Obesity Drugs Miss Sales Estimates Again, But Investors Cheer Q4 Earnings BeatEli Lilly shares rose more than 1% premarket Thursday, on track to hit levels last seen in late October, as the pharmaceutical giant posted stronger-than-expected earnings and revenue despite another ...
Weight loss drugs are huge these days, and Eli Lilly (LLY) is leading the pack when it comes to these. However, today’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback